# US 2013/0157933 A1 · Albumin fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157933 A1
- Document ID: US20130157933A1
- Status: Published application
- Kind: A1
- Application number: 13/078,804
- Filed: 2011-04-01
- Published: 2013-06-20
- Earliest claimed: 2001-12-21
- Inventors: Craig A. Rosen; William A. Haseltine; Steven M. Ruben
- Web page: https://patentgrep.com/patent/US20130157933A1

## CPC

- C07K 14/76: Albumins
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C07K 14/765: Serum albumin, e.g. HSA
- C12N 15/62: DNA sequences coding for fusion proteins
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A method of treating a human comprising administering to said human an effective amount of a pharmaceutical composition comprising an albumin fusion protein comprising two tandemly oriented GLP-1(7-36(A8G)) polypeptides fused via its C-terminus to the N-terminus of albumin comprising SEQ ID NO:327 wherein said human is obese.

### Claim 34 (depends on 33)

The method of claim 33, wherein said albumin fusion protein consists of two tandemly oriented GLP-1(7-36(A8G)) polypeptides fused via its C-terminus to the N-terminus of albumin comprising SEQ ID NO:327.

### Claim 35 (depends on 33)

The method of claim 33, wherein said pharmaceutical composition further comprises mannitol and polysorbate 80.

### Claim 36 (depends on 33)

The method of claim 33, wherein said pharmaceutical composition is buffered to pH 7.2.

### Claim 37 (depends on 36)

The method of claim 36, wherein said pharmaceutical composition is buffered by a phosphate buffer.

### Claim 38

A method of treating obesity in a human comprising administering to said human a pharmaceutical composition comprising an albumin fusion protein produced by a host cell comprising construct ID 3070, which is contained in ATCC deposit No. PTA-4671.